Monday, January 14, 2019
Bristol-Myers: EC approves Opdivo plus low dose Yervoy for treatment of RCC
Bristol-Myers announced that the European Commission has approved the combination of Opdivo 3 mg/kg plus Yervoy 1 mg/kg for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma. This decision represents the first approval of an Immuno-Oncology combination therapy for patients with this type of cancer in the European Union.
https://thefly.com/landingPageNews.php?id=2848517
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.